Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic/Myeloproliferative Diseases clinical trials
Every US clinical trial registered for Myelodysplastic/Myeloproliferative Diseases — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.
8 US clinical trials ·
The research picture
Myelodysplastic/Myeloproliferative Diseases has 8 registered US clinical trials; none are currently listed as recruiting, so most are completed or in follow-up.
- 0
- recruiting participants now
- 0%
- of trials open to enrollment
- 0
- in Phase 3–4 (later-stage)
- 2
- top sponsor: Fred Hutchinson Cancer Center
Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.
Active & Recent Trials
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
NCT00003816
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Case Comprehensive Cancer Center
NCT00054327
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders
Fred Hutchinson Cancer Center
NCT00002792
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Northwestern University
NCT00004896
Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
University of Wisconsin, Madison
NCT00052832
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00006042
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Myelodysplastic/Myeloproliferative Diseases Trial Landscape
ClinicalTrials.gov lists 8 US studies indexed under Myelodysplastic/Myeloproliferative Diseases, and 0 of those are currently open to recruitment — roughly 0% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Myelodysplastic/Myeloproliferative Diseases shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 8 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Myelodysplastic/Myeloproliferative Diseases is led by Fred Hutchinson Cancer Center with 2 indexed trials, alongside 5 other organizations in the top contributor list. The list on this page surfaces up to 8 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Myelodysplastic/Myeloproliferative Diseases?
PlainTrial tracks 8 US clinical trials for Myelodysplastic/Myeloproliferative Diseases, of which 0 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Myelodysplastic/Myeloproliferative Diseases?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.